الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
SUMMARY
Hepatitis C Virus (HCV) is a leading cause of liver cirrhosis, end stage liver disease, and hepatocellular carcinoma (HCC). The goals of HCV treatment are to achieve a sustained virological response (SVR) after treatment and for long time , to halt the progression of liver damage, and to establish conditions that may allow hepatic fibrosis to regress.
Successful treatmnt reduces fibrosis and liver-related mortality. While fibrosis regresses in most patients post-SVR, repair is frequently incomplete and cirrhosis persists in about 43.3% of patients who had cirrhosis prior to treatment.
Transient elastography (FibroScan) and ( Fib 4 ) are an attractive methods for obtaining repeated measurements because their eliminates the pain, morbidity, and mortality that can accompany liver biopsy.
The current study was conducted in The benisufe general hospital - Beni Suef, and included 50 patients, It was limited to hepatitis C-infected patients receiving treatment with DAA. liver stiffness measurement performed using FibroScan at baseline, end-of-treatment andfolloe up after 5 years from treatment.
In this study we aimed to evaluate changes in liver stiffness and fibrosis after eradication of HCV by non invasive techniques
( fibroscan and fib 4 ).
According to results we found a significant liver stiffness decrease at the end of treatment, which continued after sustained virological response 5 years after treatment (SVR) by a median -3.4 kPa, (P+ -value = 0.050) compared to baseline. Similar dynamics were observed in cirrhotic and non-cirrhotic patients.